Trademarkia Logo

Canada

C$
Trademark Search in Canada
RIBOMETRIX

View On IC.GC.CA

RIBOMETRIX
APPROVED

on 18 Feb 2025

Last Applicant/ Owned by

Ribometrix, Inc.

8 Davis DriveDurham, NC 27709

US

Serial Number

2376212 filed on 16th Jun 2020

Correspondent Address

BORDEN LADNER GERVAIS LLP

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

RIBOMETRIX

Trademark usage description

pharmaceutical preparations for the treatment of neurodegenerative diseases, cancer, hiv, hematopoietic disease and disorders, blood disorders, cardio Read More

Classification Information

Class [005]
Pharmaceutical preparations for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, viral and bacterial skin infections, infectious diseases, namely, respiratory infections, eye infections, urinary tract infections, urovaginal infections, coronavirus infection, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders; pharmaceutical preparations comprised of small molecules in the nature of organic compounds that target RNA for use in medical treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, viral and bacterial skin infections, infectious diseases, namely, respiratory infections, eye infections, urinary tract infections, urovaginal infections, coronavirus infection, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders via the induction or inhibition of gene expression; pharmaceutical preparations comprised of small molecules in the nature of organic compounds that target RNA-binding proteins for use in medical treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, viral and bacterial skin infections, infectious diseases, namely, respiratory infections, eye infections, urinary tract infections, urovaginal infections, coronavirus infection, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders via the induction or inhibition of gene expression; pharmaceutical preparations comprised of small molecules in the nature of organic compounds that target RNA and RNA-binding proteins for use in medical treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, viral and bacterial skin infections, infectious diseases, namely, respiratory infections, eye infections, urinary tract infections, urovaginal infections, coronavirus infection, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders via the induction or inhibition of gene expression; pharmaceutical preparations that contain small molecule therapeutics that target RNA for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, viral and bacterial skin infections, infectious diseases, namely, respiratory infections, eye infections, urinary tract infections, urovaginal infections, coronavirus infection, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders; pharmaceutical preparations that contain small molecule therapeutics that target RNA-binding proteins for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, viral and bacterial skin infections, infectious diseases, namely, respiratory infections, eye infections, urinary tract infections, urovaginal infections, coronavirus infection, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders; pharmaceutical preparations that contain small molecule therapeutics that target RNA and RNA-binding proteins for the treatment of neurodegenerative diseases, cancer, HIV, hematopoietic disease and disorders, blood disorders, cardiovascular diseases and disorders, genetic diseases and disorders, liver diseases and disorders, viral and bacterial skin infections, infectious diseases, namely, respiratory infections, eye infections, urinary tract infections, urovaginal infections, coronavirus infection, immune system related diseases and disorders, metabolic diseases and disorders, kidney diseases and disorders, and reproductive diseases and disorders

Classification kind code

11

Class [042]
Research and development services in the field of pharmaceuticals

Classification kind code

11

Mark Details

Serial Number

2376212

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 48
on 30th May 2022		Agent Changed
Submitted for opposition 22
on 21st Feb 2022		Search Recorded
Submitted for opposition 20
on 21st Feb 2022		Examiner's First Report
Submitted for opposition 223
on 21st Feb 2022		Total Provisional Refusal
Submitted for opposition 256
on 6th Sept 2021		Notification of Possible Opposition Sent
Submitted for opposition 257
on 5th Nov 2020		Designation Notification - Madrid Protocol
Submitted for opposition 1
on 4th Nov 2020		Created
Submitted for opposition 31
on 4th Nov 2020		Formalized
Submitted for opposition 228
on 16th Jun 2020		International Registration
Submitted for opposition 30
on 16th Jun 2020		Filed